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QUALITYOF LIFE IN PATIENTS
WITH PROSTHESIS–PATIENT
MISMATCH
To the Editor:
I read with interest the article by
Moon and colleagues1 and thank the
authors for their contribution to the
continued debate on the issue of pros-
thesis–patient mismatch (PPM).
PPM is an important topic in current
cardiac surgery, and there are several
discrepancies and contrasting publica-
tions about the effect of PPM on
postoperative outcome.2,3 Some of
these controversies are discussed in
the accompanying counterpoint article
by Dr Feindel.4 In their work Moon
and colleagues1 provide important in-
sight into the management of aortic
valve replacement (AVR) with bio-
prostheses in patients older than 70
Letters to the EditorReply to the Editor:
We thank Dr Beghetti and col-
leagues for their thoughtful comments
regarding the hemodynamic evalua-
tion and further management of our re-
cent case of atrial septal defect (ASD).1
The management of patients with a de-
gree of pulmonary vascular disease
prior to shunt closure has been a matter
of debate. In addition, recent studies
demonstrating the efficacy of oral
vasodilators in pulmonary vascular
disease associated with congenital
systemic-to-pulmonary shunts2,3 have
fueled an uncertainty of vasodilator
pretreatments prior to shunt closure.
Despite optimized medical treat-
ment with diuretics, antibiotics, and
oral anticoagulant over 4 months since
the first medical contact, our patient
was severely dyspneic, with elevated
atrial pressures, a pro–brain natriuretic
peptide serum level of above 4000 pg/
mL, and a dramatically limited 6-min-
ute walking distance (6-MWD) of 150
m. In fact, based on the hemodynamic
assessment alone, the patient was ad-
mitted to the surgical ward for ASD
closure. However, surgeons refused
the operation based on the patient’s
overall clinical profile and frailty. A
10-month treatment with bosentan on
top of supportive treatment with di-
uretics and anticoagulation effectively
decreased shunt flow and lowered
pulmonary vascular resistance by 140
dynes $ s1 $ cm5 and markedly de-
creased atrial pressures, biomarkers,
and 6-MWD in the presence of
a mild arterial desaturation.
We do agree with the discussants
that taking into account left atrial pres-786 The Journal of Thoracic andsures, pulmonary arteriolar resistance
was about 3 Woods. In addition, the
pulmonary-to-systemic resistance ra-
tio under oxygen and nitric oxide
was<0.33 (in the patient, this ratio
was 0.11), a threshold pediatric cardi-
ologists have labeled as a criterion
conveying a good prognosis after clo-
sure of the shunt.4 Still, data in adult
patients with congenital heart disease
are lacking, and the criteria of a com-
plete hemodynamic responder status
in adults were not fulfilled in this
case.5 Because hemodynamic testing
is a routine procedure in adult pulmo-
nary vascular centers, we do rely on
these data in the absence of firm evi-
dence indicating their uselessness in
adults with congenital heart disease.
Moreover, children are usually exam-
ined under general sedation/anesthe-
sia. For these and other reasons, it is
evident that the hemodynamic re-
sponse pattern in children is different
from that in adults6 and that hemody-
namic criteria in children may not ap-
ply to elderly adults. Furthermore,
later assessments after surgery in the
patient under discussion illustrated
a degree of persistent pulmonary vas-
cular disease with a pulmonary arterio-
lar resistance of 530 dynes $ s1 $ cm5,
despite active treatment with bosen-
tan.1
The main value of this report is to
provoke discussion, because due to its
single case nature, surgery in the ab-
sence of bosentan cannot be repeated.
We submit that our invasive proce-
dure was based on an integrative
clinical and hemodynamic approach
and guided by numbers, rather than
the reverse. Controlled data to guide
a ‘‘targeted treatment-and-repair’’
strategy in adult patients with congen-
ital heart disease are needed.
Konrad Hoetzenecker, MDa
Hendrik J. Ankersmit, MDa
Irene M. Lang, MDb
Departments of aCardiothoracic
Surgery and
bCardiology, Medical University of
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